- Home
- BCDA vs IMRN Comparison
BCDA vs IMRN Comparison
Compare BCDA & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- IMRN
- Stock Information
- Founded
- BCDA N/A
- IMRN 1994
- Country
- BCDA United States
- IMRN Australia
- Employees
- BCDA N/A
- IMRN N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- IMRN Health Care
- Exchange
- BCDA Nasdaq
- IMRN Nasdaq
- Market Cap
- BCDA 11.0M
- IMRN 9.2M
- IPO Year
- BCDA N/A
- IMRN N/A
- Fundamental
- Price
- BCDA $2.15
- IMRN $1.88
- Analyst Decision
- BCDA Strong Buy
- IMRN Strong Buy
- Analyst Count
- BCDA 1
- IMRN 1
- Target Price
- BCDA $25.00
- IMRN $5.00
- AVG Volume (30 Days)
- BCDA 52.3K
- IMRN 25.2K
- Earning Date
- BCDA 08-12-2025
- IMRN 07-07-2025
- Dividend Yield
- BCDA N/A
- IMRN N/A
- EPS Growth
- BCDA N/A
- IMRN N/A
- EPS
- BCDA N/A
- IMRN N/A
- Revenue
- BCDA $3,000.00
- IMRN $4,048,286.00
- Revenue This Year
- BCDA N/A
- IMRN N/A
- Revenue Next Year
- BCDA N/A
- IMRN N/A
- P/E Ratio
- BCDA N/A
- IMRN N/A
- Revenue Growth
- BCDA N/A
- IMRN 82.90
- 52 Week Low
- BCDA $1.63
- IMRN $1.50
- 52 Week High
- BCDA $4.66
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- BCDA 51.13
- IMRN 58.70
- Support Level
- BCDA $1.98
- IMRN $1.68
- Resistance Level
- BCDA $2.45
- IMRN $1.94
- Average True Range (ATR)
- BCDA 0.17
- IMRN 0.09
- MACD
- BCDA 0.01
- IMRN 0.02
- Stochastic Oscillator
- BCDA 53.19
- IMRN 76.92
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.